<DOC>
	<DOCNO>NCT01445938</DOCNO>
	<brief_summary>Primary Objective : To assess antiparasitic activity intramuscular ( IM ) SAR97276A base parasite reduction ratio 72 hour pediatric patient uncomplicated malaria Secondary Objectives : - To assess evolution clinical sign symptom ( include need rescue therapy ) pediatric patient uncomplicated malaria receive SAR97276A reference Artemisinin-Based Combination Therapy ( ACTs ) - To assess pharmacokinetics profile SAR97276A pediatric patient uncomplicated malaria - To assess safety profile SAR97276A pediatric patient uncomplicated malaria - To assess pharmacokinetic-pharmacodynamic relationship SAR97276A</brief_summary>
	<brief_title>Anti-parasitic Activity Safety Assessment SAR97276A Children With Uncomplicated Malaria</brief_title>
	<detailed_description>The total duration per patient last approximately 28 ± 2 day break follow : - A screening phase 12-hours - A 28 ± 2 day study period</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Antiparasitic Agents</mesh_term>
	<criteria>Inclusion criterion : Patients diagnose symptomatic infection Plasmodium falciparum microscopically confirm blood smear Day1 visit Fever ( tympanic rectal temperature ≥ 38 C ) document history fever within last 24h Asexual parasitemia ≥ 2 000 parasites/μL blood smear D1 visit Signed Informed Consent Form parent legal guardian Age : 12 17 year old step 1 Age : 2 11 year old step 2 step 3 Exclusion criterion : Participation another clinical trial within last 3 month participation within different cohort PDY11737 clinical trial participation previous trial SAR97276 Documented history adequate treatment antimalarial expect effective within precede 72 hour Severe concomitant disease ( include concomitant febrile illnesses infection ) Any sign suggestive severe malaria Severe malnutrition Asexual parasitemia : Plasmodium falciparum &gt; 100,000 parasites/μL blood smear D1 visit Previous treatment within 3 week prior inclusion , concomitant treatment potent CYP3A4 inhibitor CYP3A4 inducer CYP2D6 substrates potent CYP2D6 inhibitor Known serious adverse event reaction hypersensitivity ArtemisininBased Combination Therapy ( ACTs ) contraindication positive control therapy ( Artemisinin Combined Treatments ) warning/precaution use define respective National Product Labeling Pregnant breastfeed woman Women childbearing potential protected effective contraceptive method birth control , willing use effective contraceptive ( ) method ( ) duration study ( e.g . : double barrier method ) , and/or unwilling unable test pregnancy , CPK 3 ULN , Underlying hepatobiliary disease ALT &gt; 3 ULN . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>